61980 Federal Register / Vol. 71, No. 203 / Friday, October 20, 2006 / Notices 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). The meeting will be open to the 

public. 

Name of Committee: Arthritis 

Advisory Committee. 

General Function of the Committee: 

To provide advice and 

recommendations to the agency on 

FDA’s regulatory issues. 

Date and Time: The meeting will be 

held on November 29, 2006, from 8 a.m. 

to 5 p.m. 

Location: Hilton Washington DC 

North/Gaithersburg, The Ballrooms, 620 

Perry Pkwy., Gaithersburg, MD. 

Contact Person: Johanna M. Clifford, 

Center for Drug Evaluation and Research 

(HFD–21), Food and Drug 

Administration, 5600 Fishers Lane (for 

express delivery, 5630 Fishers Lane, rm. 

1093), Rockville, MD 20857, 301–827–

7001, FAX: 301–827–6776, e-mail: 

Johanna.Clifford@fda.hhs.gov, or FDA 

Advisory Committee Information Line, 

1–800–741–8138 (301–443–0572 in the 

Washington, DC area), code 

3014512532. Please call the Information 

Line for up-to-date information on this 

meeting. The background material will 

become available no later than the day 

before the meeting and will be posted 

on FDA’s Web site at http:// 

www.fda.gov/ohrms/dockets/ac/ 

acmenu.htm under the heading 

‘‘Arthritis Advisory Committee.’’ (Click 

on the year 2006 and scroll down to the 

above named committee meeting). 

Agenda: The committee will discuss 

the safety and efficacy of the 

nonsteriodal anti-inflammatory drug 

(COX–2 inhibitor) new drug application 

(NDA) 20–998/S021, CELEBREX 

(celecoxib), Pfizer, Inc., for the proposed 

indication of the relief of the signs and 

symptoms of juvenile rheumatoid 

arthritis in patients 2 years and older. 

Procedure: Interested persons may 

present data, information, or views, 

orally or in writing, on issues pending 

before the committee. Written 

submissions may be made to the contact 

person on or before November 15, 2006. 

Oral presentations from the public will 

be scheduled between approximately 

11:30 a.m. and 12:30 p.m. Time allotted 

for each presentation may be limited. 

Those desiring to make formal oral 

presentations should notify the contact 

person and submit a brief statement of 

the general nature of the evidence or 

arguments they wish to present, the 

names and addresses of proposed 

participants, and an indication of the 

approximate time requested to make 

their presentation on or before 

November 15, 2006. 

Persons attending FDA’s advisory 

committee meetings are advised that the 

agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee 

meetings and will make every effort to 

accommodate persons with physical 

disabilities or special needs. If you 

require special accommodations due to 

a disability, please contact Johanna 

Clifford at least 7 days in advance of the 

meeting. 

Notice of this meeting is given under 

the Federal Advisory Committee Act (5 

U.S.C. app. 2). 

Dated: October 13, 2006. 

Randall W. Lutter, 

Associate Commissioner for Policy. 

[FR Doc. 06–8787 Filed 10–19–06; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

Neurological Devices Panel of the 

Medical Devices Advisory Committee; 

Notice of Postponement of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

The Food and Drug Administration 

(FDA) is postponing the meeting of the 

Neurological Devices Panel scheduled 

for October 31, 2006. The meeting was 

announced in the Federal Register of 

September 22, 2006 (71 FR 55491). 

FDA’s Center for Devices and 

Radiological Health will further 

evaluate data relevant to the topic. A 

future meeting date will be announced 

in the Federal Register. 

Contact Person: Janet L. Scudiero, 

Center for Devices and Radiological 

Health (HFZ–410), Food and Drug 

Administration, 9200 Corporate Blvd., 

Rockville, MD 20850, 301–594–1184, or 

FDA Advisory Committee Information 

Line, 1–800–741–8138 (301–443–0572 

in the Washington, DC area), code 

3014512513. Please call the Information 

Line for up-to-date information on this 

meeting. 

Dated: October 13, 2006. 

Randall W. Lutter, 

Associate Commissioner for Policy and 

Planning. 

[FR Doc. 06–8788 Filed 10–19–06; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

Circulatory System Devices Panel of 

the Medical Devices Advisory 

Committee; Notice of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). The meeting will be open to the 

public. 

Name of Committee: Circulatory 

System Devices Panel of the Medical 

Devices Advisory Committee. 

General Function of the Committee: 

To provide advice and 

recommendations to the agency on 

FDA’s regulatory issues. 

Date and Time: The meeting will be 

held on December 7 and 8, 2006, from 

8 a.m. to 5:30 p.m. 

Location: Hilton Washington DC 

North/Gaithersburg, Salons A, B, and C, 

620 Perry Pkwy., Gaithersburg, MD. 

Contact Person: James Swink, Center 

for Devices and Radiological Health 

(CDRH) (HFZ–450), Food and Drug 

Administration, 9200 Corporate Blvd., 

Rockville, MD 20850, 301–443–8262, 

ext. 163, or FDA Advisory Committee 

Information Line, 1–800–741–8138 

(301–443–0572 in the Washington, DC 

area), code 3014512625. Please call the 

Information Line for up-to-date 

information on this meeting. 

Agenda: The committee will discuss 

and make recommendations regarding 

issues related to stent thrombosis in 

coronary drug-eluting stents. 

Background information for the topic, 

including the agenda and questions for 

the committee, will be available to the 

public 1 business day before the 

meeting on the Internet at http:// 

www.fda.gov/cdrh/panel (click on 

Upcoming CDRH Advisory Panel/ 

Committee Meetings). 

Procedure: Interested persons may 

present data, information, or views, 

orally or in writing, on issues pending 

before the committee. Written 

submissions may be made to the contact 

person on or before November 15, 2006. 

Oral presentations from the public will 

be scheduled on both days for 

approximately 1 hour at the beginning 

of committee deliberations and for 

approximately 1 hour near the end of 

the deliberations. Time allotted for each 

presentation may be limited. Those 

desiring to make formal oral 

presentations should notify the contact 


jlentini on PROD1PC65 with NOTICES